Protein identified that serves as a “brake” on inflammation

Memphis, Tennessee, April 21, 2015

 

Results of the St. Jude Children’s Research Hospital-led study provide a target for developing novel therapies to tame the inflammation that drives autoinflammatory diseases

Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis (MS), colitis and other autoimmune disorders. St. Jude Children’s Research Hospital scientists led the study which appears today in the scientific journal Immunity.

Investigators showed that the protein NLRP12 works in T cells to limit production of chemical messengers or cytokines that fuel inflammation. T cells are specialized white blood cells produced to eliminate specific infectious agents and other threats. Deletion of the Nlrp12 gene led to increased cytokine production in T cells. Specially bred mice that received T cells deficient in the protein NLRP12 developed more severe symptoms of colitis and the chronic skin condition atopic dermatitis.

The results suggest how mutations in the Nlrp12 gene cause disease, which until now was unclear. “We have identified a possible mechanism of how mutations in Nlrp12 lead to atopic dermatitis and possibly other diseases in humans,” said corresponding author Thirumala-Devi Kanneganti, Ph.D., a member of the St. Jude Department of Immunology. “Understanding the precise inner-workings of NLRP12 in T cells will help guide efforts to develop therapies to ease symptoms by taming inflammation driven by T cells.”

Researchers also found that NLRP12-deficient mice may offer a much needed mouse model for studying the development of balance and movement problems in people with multiple sclerosis (MS).

NLRP12 belongs to a family of proteins best known for working in the innate immune system to help cells sense threats and then launch the inflammatory response to eliminate them. The innate immune system is the body’s first line of defense. It works with T cells and other components of the adaptive immune system to safeguard health.

Previous research from Kanneganti’s laboratory showed that rather than fueling production of the cytokines that drive inflammation, NLRP12 played a different role in the innate immune response. Researchers showed that in the innate immune system, NLRP12 worked in the NF-kB signaling pathway to restrain inflammation.

The latest study showed that NLRP12 serves the same anti-inflammatory function in T cells. Investigators demonstrated that NLRP12 works through the NF-kB pathway in T cells to regulate production of interleukin 4 (IL-4) and other cytokines.

“This study provides the first evidence that NLRP12 can function in adaptive immune cells to regulate inflammation and impact various autoimmune disorders,” Kanneganti said. “That’s important because excessive inflammation plays a role in many human diseases, including cancer.”

The findings could also advance efforts to understand and treat MS, a chronic inflammatory disorder in which T cells attack and damage the myelin sheath that insulates nerve fibers. The resulting demyelination disrupts nervous system functioning, causing MS symptoms.

Demyelination and inflammation both occur in the current mouse model of MS and result in progressive paralysis beginning in the tail. Surprisingly, the deletion of Nlrp12 in mice led to different symptoms. The mice had less paralysis, but developed problems with balance and movement, just like MS patients. Investigators linked the new symptoms to increased IL-4 production by T cells that lacked NLRP12. When excess IL-4 was eliminated using various methods, the mice again exhibited classical paralysis rather than the other symptoms related to balance and movement.

The study’s first author is John Lukens, Ph.D., formerly of St. Jude and now of the University of Virginia. The second author is Prajwal Gurung, Ph.D., a St. Jude postdoctoral fellow who contributed significantly to the study. The other authors are Patrick Shaw, Maggie Barr, Scott Brown, Peter Vogel and Hongbo Chi, all of St. Jude; and Md. Hasan Zaki, formerly of St. Jude and now of the University of Texas Southern Medical School, Dallas.

The study was funded in part by grants (AR056296, CA163507, AI101935) from the National Institutes of Health and ALSAC.

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow the hospital on Twitter and Instagram at @stjuderesearch.